recombinant grass pollen allergy desensitization injection (ALK-Abello)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namerecombinant grass pollen allergy desensitization injection (ALK-Abello)
Drug Alias NameAllergy Therapeutic (Maxygen/ALK-Abello)Recombinant Grass Pollen Allergen (ALK-Abello)Maxy-20
ClassificationBiologics > Protein drugs > Recombinant proteinVaccines
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHypersensitivity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMaxygen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMaxygenALK Abello AS
Active IndicationsN/A
Inactive IndicationsHypersensitivity

Other Information

ATC CodeN/A
Related LinksN/A